An advertorial by Hamlet Pharma was published in The Guardian on December 6th. Entitled “Successful new drug candidate for patients with bladder cancer – from…
Read More
Colorectal cancer is a leading cause of death world-wide and more than 180,000 cases are diagnosed annually in the US alone. We now show that…
Hamlet Pharma develops new drug candidates to treat cancer without causing significant side effects. The drug candidate Alpha1H shows specificity for tumor tissue, where it…
MON, JUN 13, 2022 14:41 CETToday, Hamlet Pharma signed a joint development agreement with Neurochase Limited, founded by Professor Steven Gill, a world leading expert…
Hamlet Pharma has participated in a number of recent events, presenting highligts from the promising clinical studies and our future strategy. With this newsletter, we…
Hamlet Pharma enters a new business development phase involving multiple cancer indications and markets. Based on the successful outcomes of our clinical trial program, we…
Hamlet Pharma has recently delivered its 18-month report to the Euro- pean Union’s Horizon 2020 program. In their response, the EU states that the project…
Pressmeddelande Hamlet Pharma deltar på Stockholm Corporate Finance 14e Life Science Kapitalmarknadsdagar den 8 – 9 mars 2022. Catharina och Mats presenterar den 8 mars…
Hamlet-Pharma-Newsletter-Dose-escalationDownload
Read More
MON, JAN 17, 2022 12:15 CET Hamlet Pharma has previously reported the successful completion of a Phase I/II study using a 1.7 mM dose of…